SODa-BIC on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Daniel Ramirez and Urvashi Khan
FIND-CKD trial on Instagram
FIND-CKD on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Andreea Manolea
Bonus: more on finerenone in proteinuric CKD universe- visuals by Cristina Popa
TRACK trial on Instagram
TRACK trial on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa
Buffering without benefit? The SODa-BIC study
On the right TRACK? Rivaroxaban to prevent cardiovascular events in advanced CKD.
Making an IMPACT on BP: Why pills alone won't win the war
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
Inhibidor de TRPC6: El Resumen Visual
Por primera vez, una terapia dirigida al podocito muestra eficacia clínica en GEFyS. Esta semana #NephJC revisa el ECA fase 2 de BI 764198, inhibidor oral de TRPC6, que redujo proteinuria, estabilizó el FGe y fue bien tolerado. ¿El inicio de una nueva era en GEFyS? Revisa el resumen visual por la Dra Divya Bajpai
TRPC6 inhibition: The Visual Abstract
For the first time, a podocyte-targeted therapy shows clinical efficacy in FSGS. This week #NephJC covers the phase 2 RCT of BI 764198, an oral TRPC6 inhibitor that lowered proteinuria, preserved eGFR, and was well tolerated. A new era in FSGS? Check out the visual abstract by Divya Bajpai
Searchin’ For My Lost Shaker of Salt- Targeted Treatment of Hyponatremia
NephJC Short: The Push Trial
NephJC Covers LBCTs at the World Congress
INFINITI: The Visual Abstract
SGLT2i have reshaped cardiorenal care, but kidney transplant recipients have mostly been left out of the story. INFINITI starts to close that gap, testing the safety and physiology of dapagliflozin in stable KTR.
Do #flozins behave the same in transplanted kidneys? Check out the VA by Janany Sabescumar
INFINITI: El Resumen Visual
Los iSGLT2 han revolucionado la protección cardiorrenal, pero los trasplantados renales han quedado fuera de la historia. El ensayo INFINITI empieza a cerrar esa brecha. ¿Flozinaran igual los iSGLT2 en el riñón trasplantado? Revisa el resumen visual creado por Janany Sabescumar
To INFINITI and Beyond: SGLT2 Inhibitors in Kidney Transplant Patients
POTCAST- K+ Pop and Arrhythmia Drop
POTCAST: The Visual Abstract
Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
TenPosts: pegcetacoplan in C3GN
Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan Agavriloaei.
A ray of hope APPEARS for C3G
A VALIANT effort to combat complement disorders with pegcetacoplan
VALIANT: The Visual Abstract
The VALIANT phase 3 RCT shows that proximal C3 inhibition with pegcetacoplan leads to a significantly greater reduction in proteinuria compared with placebo in patients with C3G and primary immune-complex MPGN. This trial builds on prior upstream complement strategies and strengthens the case for disease-targeted therapy in C3G.
Check out the VA Dr. Akshaya Jayachandran and don´t forget to join #NephJC on bluesky.